Calycosin Inhibit PANoptosis and Alleviate Brain Damage: A Bioinformatics and Experimental Verification Approach by Huiyan An (20959966)

Subjects:

Number of <i>aP2-Drp1</i>^f/f (KO: Fabp4 Cre^+/--<i>Drp1</i>^flox/flox), <i>aP2-Drp1</i>^f/+ (Hetero: Fabp4 Cre^+/--<i>Drp1</i><su... by Yuta Ibayashi (20404811)

Subjects:

β-diversity of intestinal microbiota from healthy and diseased shrimp. by Lalitphan Kitsanayanyong (19353505)

Subjects:

The spheroid assay is used to assess long-term effects of therapy on tumor cell by culturing the tumor cells in a micro-mass, which is a 3D tumor mass used as a surrogate for in vi... by Bryan S. Margulies (21492667)

Subjects:

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Comparison of 1^st, 2^nd, and 3^rd antibiotic prescription. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Unique intestinal microbiota in healthy shrimp. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Unique intestinal microbiota in diseased shrimp. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Taxa bar plot of intestinal microbiota from healthy and diseased shrimp at the genus level. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Taxa bar plot of intestinal microbiota from healthy and diseased shrimp at the class level. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Taxa bar plot of intestinal microbiota from healthy and diseased shrimp at the phylum level. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Taxa bar plot of intestinal microbiota from healthy and diseased shrimp at the family level. by Lalitphan Kitsanayanyong (19353505)

Subjects:

α-diversity indices of intestinal microbiota from healthy and diseased shrimp. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Heat map of intestinal microbiota from healthy and diseased shrimp at the genus level. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX by Sofia Schaeffer (20379954)

“…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”